 Leap Therapeutics NASDAQ:LPTX shares are trading higher after the company announced it presented updated results for its DKN-01 plus tislelizumab which showed compelling activity in first-line patients with gastric, gastroesophageal junction cancer. Leap Therapeutics stock is trading up 38.86 to a price of 2.68. 